Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

They used propensity matching to compare 1,925 adolescents who took semaglutide (Wegovy), liraglutide (Saxenda), dulaglutide ...

Wegovy and Ozempic drove Novo Nordisk to record bumper sales ... of Novo Nordisk’s other popular GLP-1 category drug ...

The FDA warns GLP-1 weight loss drug users of aspiration risks during anaesthesia Learn what this update means and how to ...

Labels of all GLP-1 receptor agonists now carry a warning about pulmonary aspiration during general anesthesia or deep ...

Only 13 states currently allow Medicaid to cover GLP-1 agonist drugs for obesity treatment, highlighting a significant gap in ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

The drugs affected by the new warning include: Semaglutide, with brand names Ozempic, Rybelsus, and Wegovy Liraglutide, which ...

A DAD died after taking a weight loss jab for just a few weeks. Tim Ramsay, from South Australia, wanted to shed some pounds so he could confidently walk his daughter down the aisle. The ...

The FDA has updated the labels for all GLP-1 receptor agonists, including popular medications Ozempic, Wegovy, Saxenda and Mounjaro, to include a new warning about the risk of pulmonary aspiration ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...